Drug Profile
Favipiravir - Sihuan Pharmaceutical Holdings Group
Alternative Names: jk 05Latest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Academy of Military Medical Sciences
- Developer Sihuan Pharmaceutical Holdings Group
- Class Small molecules
- Mechanism of Action RNA inhibitors; RNA replicase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bunyavirus infections; COVID 2019 infections; Ebola virus infections; Influenza virus infections; Viral haemorrhagic fevers; Yellow fever